Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Remote Consultation | 3 | 2021 | 42 | 1.000 |
Why?
|
| Anti-Obesity Agents | 3 | 2021 | 45 | 0.840 |
Why?
|
| General Practice | 1 | 2023 | 27 | 0.820 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 321 | 0.750 |
Why?
|
| Obesity | 5 | 2021 | 2508 | 0.730 |
Why?
|
| Medicine | 1 | 2021 | 102 | 0.640 |
Why?
|
| Weight Reduction Programs | 1 | 2019 | 94 | 0.610 |
Why?
|
| Insulinoma | 1 | 2018 | 29 | 0.610 |
Why?
|
| Confusion | 1 | 2018 | 25 | 0.600 |
Why?
|
| Weight Loss | 2 | 2019 | 642 | 0.600 |
Why?
|
| Cardiology | 1 | 2020 | 259 | 0.580 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 833 | 0.520 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 90 | 0.500 |
Why?
|
| Insulin Antibodies | 1 | 2016 | 102 | 0.500 |
Why?
|
| Rituximab | 1 | 2016 | 150 | 0.490 |
Why?
|
| Cognition Disorders | 1 | 2018 | 476 | 0.450 |
Why?
|
| Immunologic Factors | 1 | 2016 | 220 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 2096 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 238 | 0.440 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 382 | 0.410 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 1727 | 0.410 |
Why?
|
| Referral and Consultation | 3 | 2023 | 635 | 0.410 |
Why?
|
| Hypoglycemic Agents | 3 | 2022 | 1013 | 0.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 373 | 0.400 |
Why?
|
| Hypoglycemia | 1 | 2016 | 387 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 731 | 0.370 |
Why?
|
| Veterans | 3 | 2021 | 1249 | 0.370 |
Why?
|
| Blood Glucose | 3 | 2022 | 1828 | 0.320 |
Why?
|
| Insulin | 1 | 2016 | 2080 | 0.270 |
Why?
|
| Primary Health Care | 3 | 2021 | 1514 | 0.260 |
Why?
|
| Life Style | 2 | 2021 | 430 | 0.250 |
Why?
|
| Humans | 21 | 2023 | 114698 | 0.220 |
Why?
|
| Veterans Health | 2 | 2021 | 165 | 0.200 |
Why?
|
| Telephone | 1 | 2023 | 153 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2021 | 4895 | 0.190 |
Why?
|
| Obesity Management | 1 | 2021 | 8 | 0.190 |
Why?
|
| Chylomicrons | 1 | 2021 | 6 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 34 | 0.180 |
Why?
|
| Behavior Therapy | 2 | 2021 | 226 | 0.180 |
Why?
|
| Transgender Persons | 1 | 2023 | 135 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 138 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 900 | 0.180 |
Why?
|
| Capacity Building | 1 | 2021 | 51 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2005 | 574 | 0.170 |
Why?
|
| Specialization | 1 | 2021 | 115 | 0.170 |
Why?
|
| PPAR gamma | 1 | 2021 | 182 | 0.170 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 222 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 159 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 276 | 0.160 |
Why?
|
| Safety-net Providers | 1 | 2019 | 95 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 411 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 1320 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2021 | 9088 | 0.140 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 86 | 0.140 |
Why?
|
| Male | 9 | 2021 | 55606 | 0.140 |
Why?
|
| Urban Population | 1 | 2019 | 397 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 67 | 0.120 |
Why?
|
| Exercise | 1 | 2005 | 1644 | 0.120 |
Why?
|
| Adult | 7 | 2022 | 30553 | 0.120 |
Why?
|
| Middle Aged | 6 | 2021 | 26738 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 429 | 0.120 |
Why?
|
| Depression | 1 | 2021 | 1134 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 607 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2016 | 505 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 927 | 0.090 |
Why?
|
| Mutation | 1 | 2021 | 3346 | 0.090 |
Why?
|
| Female | 7 | 2021 | 59520 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2286 | 0.080 |
Why?
|
| Aged | 4 | 2021 | 19074 | 0.070 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2007 | 8 | 0.070 |
Why?
|
| United States | 2 | 2020 | 12186 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 114 | 0.070 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 79 | 0.060 |
Why?
|
| Diet, Atherogenic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2540 | 0.050 |
Why?
|
| England | 1 | 2021 | 65 | 0.050 |
Why?
|
| Time | 1 | 2021 | 70 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 68 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2021 | 76 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 90 | 0.050 |
Why?
|
| Homozygote | 1 | 2021 | 187 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 158 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 67 | 0.040 |
Why?
|
| Efficiency | 1 | 2021 | 84 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2021 | 130 | 0.040 |
Why?
|
| Heterozygote | 1 | 2021 | 251 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 72 | 0.040 |
Why?
|
| Pedigree | 1 | 2021 | 460 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2021 | 120 | 0.040 |
Why?
|
| Health Care Reform | 1 | 2021 | 92 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 183 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 4624 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 696 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2021 | 482 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 8632 | 0.040 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 161 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2021 | 249 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 544 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 381 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 819 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 287 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 897 | 0.030 |
Why?
|
| Endocrinology | 1 | 2016 | 70 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 681 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 763 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 534 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1448 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 12555 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 2086 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2387 | 0.020 |
Why?
|
| Colorado | 1 | 2021 | 4100 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4410 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 7964 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 9118 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2007 | 28 | 0.020 |
Why?
|
| Diabetic Foot | 1 | 2007 | 22 | 0.020 |
Why?
|
| Vibration | 1 | 2007 | 58 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 10471 | 0.020 |
Why?
|
| Child | 1 | 2021 | 18420 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 2765 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 3252 | 0.010 |
Why?
|